Close Menu

NEW YORK (GenomeWeb) – Roche today announced the final results of its tender offer to purchase up to 15.6 million shares of common stock of Foundation Medicine at $50 per share, after disclosing preliminary results last week.

Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock. Because the offer was oversubscribed, Roche will accept 83.2 percent of shares offered by each tendering stockholder for purchase.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.